FDA Approves New Weight Loss Pill, Foundayo, in Record Time - Drugs.com MedNews THURSDAY, April 2, 2026 A new daily pill to help with weight loss has been approved by the U.S. Food and Drug Administration (FDA), and it moved through review

The FDA approved #Foundayo, a new daily weight loss pill from Eli Lilly, 294 days ahead of schedule. It's the fastest approval of a new drug type since 2002. It targets GLP-1 receptors, similar to injectable weight loss drugs. Side effects and serious risks apply. www.drugs.com/news/fda-app...

The first ever non-peptide GLP-1 agonist just received approval from @fda.gov for @elilillyandcompany.bsky.social. What will #Foundayo (orforglipron) and the competition with Wegovy tablets bring to obesity care? We have some ideas.
conscienhealth.org/2026/04/02/w...

Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.

#EliLilly has claimed US approval for oral GLP-1 agonist #orforglipron (under the name #Foundayo) setting up a market clash with #NovoNordisk 's first-to-market #Wegovy pill.

Eli Lilly's Foundayo™ Receives FDA Approval for Flexible Weight Loss Treatment Eli Lilly's Foundayo™ (orforglipron) is a groundbreaking GLP-1 weight loss pill approved by the FDA, offering treatment flexibility for obesity.

Eli Lilly's Foundayo™ Receives FDA Approval for Flexible Weight Loss Treatment #United_States #Indianapolis #Eli_Lilly #Orforglipron #Foundayo